Coronary stent thrombosis in patients with chronic kidney disease: Balancing anti-ischemic efficacy and hemorrhagic risk

Catheterization and Cardiovascular Interventions

Volumn 80, Issue 3, 2012, Pages 368-369

  Belardi, Jorge A ^a   Albertal, Mariano ^a  

^a INSTITUTO CARDIOVASCULAR DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HIRULOG; TICAGRELOR;

BLEEDING; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE SEVERITY; DRUG ELUTING STENT; DRUG MEGADOSE; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; MORTALITY; RISK FACTOR; RISK REDUCTION; STENT THROMBOSIS; SURGICAL APPROACH;

CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; RENAL INSUFFICIENCY, CHRONIC;

EID: 84865656259     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24568     Document Type: Editorial

References (21)

1. Best PJ, Reddan DN, Berger PB, Szczech LA, McCullough PA, Califf RM,. Cardiovascular disease and chronic kidney disease: Insights and an update. Am Heart J 2004; 148: 230-242. (Pubitemid 39092788)
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS,. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
3. Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, Kristensen SD, Herrmann HC, Moliterno DJ,. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 2005; 149: 869-875. (Pubitemid 40718884)
4. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB,. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-1119. (Pubitemid 34267412)
5. Hanna EB, Chen AY, Roe MT, Wiviott SD, Fox CS, Saucedo JF,. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2011; 4: 1002-1008.
6. Keough-Ryan TM, Kiberd BA, Dipchand CS, Cox JL, Rose CL, Thompson KJ, Clase CM,. Outcomes of acute coronary syndrome in a large Canadian cohort: Impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis 2005; 46: 845-855. (Pubitemid 41505458)
7. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678. (Pubitemid 46281313)
8. Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011; 123: 1745-1756.
9. Lambert ND, Sacrinty MT, Ketch TR, Turner SJ, Santos RM, Daniel KR, Applegate RJ, Kutcher MA, Sane DC,. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am Heart J 2009; 157: 688-694.
10. Choi DH, Park KW, Yang HM, Lee HY, Park JS, Kang HJ, Kim YJ, Koo BK, Oh BH, Park YB, et al. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. Int J Cardiol 2011; 149: 174-181.
11. Miao Y, Yu-Jie Z, Zhi-Jian W, Dong-Mei S, Yu-Yang L, Ying-Xin Z, Fei G, Shi-Wei Y, De-An J,. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents. Catheter Cardiovasc Interv 2012; DOI: 10.1002/ccd.23464.
12. Simsek C, Magro M, Boersma E, Onuma Y, Nauta S, Valstar G, van Geuns RJ, van der Giessen W, van Domburg R, Serruys P,. Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years. Catheter Cardiovasc Interv 2012; 80: 18-26.
13. Park SH, Kim W, Park CS, Kang WY, Hwang SH,. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009; 104: 1292-1295.
14. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010; 122: 1056-1067.
15. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-Year results of a randomised controlled trial. Lancet 2009; 374: 1149-1159.
16. Marso SP, Amin AP, House JA, Kennedy KF, Spertus JA, Rao SV, Cohen DJ, Messenger JC, Rumsfeld JS,. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA 2010; 303: 2156-2164.
17. Chew DP, Bhatt DL, Kimball W, Henry TD, Berger P, McCullough PA, Feit F, Bittl JA, Lincoff AM,. Bivalirudin provides increasing benefit with decreasing renal function: A meta-analysis of randomized trials. Am J Cardiol 2003; 92: 919-923. (Pubitemid 37214802)
18. Holmes DR, Jr., Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD, Popma JJ, Serruys PW, Kimura T, Williams DO, et al. Thrombosis and drug-eluting stents: An objective appraisal. J Am Coll Cardiol 2007; 50: 109-118. (Pubitemid 47007739)
19. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S,. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-1687. (Pubitemid 37243654)
20. Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, Sangiorgi D, Reggiani LB, Kaiser C, Kim HS, et al. Stent thrombosis with everolimus-eluting stents: Meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012; 5: 357-364.
21. Mahmoudi M, Delhaye C, Wakabayashi K, Ben-Dor I, Gonzalez MA, Maluenda G, Gaglia MA Jr, Torguson R, Xue Z, Suddath WO, et al. Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents. Am J Cardiol 2011; 107: 1757-1762.